Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12438618 | 0.91 | ADRB2 (0.35) | ADRB2PARP1WNT3ATNKS2OPRM1 | |
| SCHEMBL12438642 | 0.83 | ADRB2 (0.38) | ADRB2PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL14648516 | 0.82 | STAT3 (0.40) | ADRB2PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL14648508 | 0.82 | ADRB2 (0.39) | ADRB2PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL12440353 | 0.81 | PARP1 (0.38) | ADRB2PARP1WNT3ATNKS2OPRM1 | |
| SCHEMBL14648515 | 0.80 | STAT3 (0.40) | ADRB2PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL12438834 | 0.77 | HTR2C (0.43) | ADRB2PARP1HTTHAVCR2 | |
| SCHEMBL14648520 | 0.74 | ADRB2 (0.35) | ADRB2PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL12440352 | 0.72 | HTR2A (0.40) | ADRB2PARP1HTTHAVCR2 | |
| SCHEMBL12438619 | 0.70 | ADRB2 (0.37) | ADRB2PARP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532665-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XUANZHU PHARMA CO LTD (CN) | 2016-09-07 | — | — | EP | disclosed |
| US-20160176892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2016-06-23 | — | — | US | disclosed |
| US-9315513-B2 | Benzimidazole derivatives and their pharmaceutical compositions and uses | Xuanzhu Pharma Co., Ltd. (CN) | 2016-04-19 | — | — | US | disclosed |
| EP-2532665-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011095057-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 山东轩竹医药科技有限公司 (CN) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | F12, HRH2, H1-3 | ADRB2 747/4885PARP1 1226/4885WNT3A 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.